Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations

World Journal of Gastroenterology

Volumn 21, Issue 36, 2015, Pages 10274-10289

  Mori, Shunsuke ^a   Fujiyama, Shigetoshi ^b  

^a Kumamoto Saishunsou National Hospital   (Japan)

^b Kumamoto Shinto General Hospital   (Japan)

Author keywords

Antirheumatic therapy; Hepatitis B virus; Occult hepatitis B virus carrier; Reactivation; Resolved hepatitis B virus infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEPATITIS B SURFACE ANTIGEN; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CHINA; DEATH; DRUG EFFECT; HEPATITIS B; HUMAN; IMMUNOREGULATION; INFECTION PREVENTION; JAPAN; LIVER FAILURE; PREVALENCE; RECURRENCE RISK; RECURRENT VIRUS INFECTION; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; SCREENING; SEROLOGY; SOUTH KOREA; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION; DRUG EFFECTS; HEPATITIS B VIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PATHOGENICITY; RECURRENT DISEASE; RHEUMATIC DISEASES; RISK FACTOR; VIROLOGY; VIRUS ACTIVATION;

ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; PREVALENCE; RECURRENCE; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS; VIRUS ACTIVATION;

EID: 84942320360     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i36.10274     Document Type: Review

References (135)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219 [PMID: 22273662 DOI: 10.1016/j.vaccine.2011.12.116]
2. Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, Suzuki K, Miyakawa Y, Yoshizawa H. Sex-and agespecific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40 [PMID: 15044834 DOI: 10.1159/000076640]
3. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-S181 [PMID: 16447285 DOI: 10.1002/hep.20956]
4. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82: 967-975 [PMID: 17673066 DOI: 10.4065/82.8.967]
5. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165 [PMID: 19399803 DOI: 10.1002/hep.22945]
6. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013; 33: 167-177 [PMID: 23749673 DOI: 10.1055/s-0033-1345722]
7. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69 [PMID: 11187122 DOI: 10.1056/NEJM200101043440120]
8. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68 [PMID: 16831590 DOI: 10.1053/j.gastro.2006.04.015]
9. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]
10. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20: 2013-2017 [PMID: 19561036 DOI: 10.1093/annonc/mdp230]
11. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-262 [PMID: 19697028 DOI: 10.1007/s00277-009-0806-7]
12. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010; 28: 5097-5100 [PMID: 20837949 DOI: 10.1200/JCO.2010.29.7531]
13. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486 [PMID: 12150847 DOI: 10.1016/S1473-3099(02)00345-6]
14. Raimondo G, Pollicino T, Romanò L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 2010; 58: 254-257 [PMID: 20303674 DOI: 10.1016/j.patbio.2010.02.003]
15. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108 [PMID: 8837608 DOI: 10.1038/nm1096-1104]
16. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742 [PMID: 9620351 DOI: 10.1002/hep.510270638]
17. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26 [PMID: 10387938 DOI: 10.1056/NEJM199907013410104]
18. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495 [PMID: 10655275 DOI: 10.1002/hep.510310232]
19. Cabrerizo M, Bartolomé J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32: 116-123 [PMID: 10869298 DOI: 10.1053/jhep.2000.8541]
20. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45: 277-285 [PMID: 17256766 DOI: 10.1002/hep.21529]
21. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170 [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007]
22. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188 [PMID: 1983820]
23. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47: e52-e56 [PMID: 18643758 DOI: 10.1086/590968]
24. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23 [PMID: 19544079 DOI: 10.1007/s12185-009-0359-5]
25. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2012; 42: 627-636 [PMID: 22686858 DOI: 10.1111/j.1872-034X.2012.00998.x]
26. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]
27. Rotman Y, Brown TA, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology 2009; 49: S22-S27 [PMID: 19399815 DOI: 10.1002/hep.22976]
28. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657 [PMID: 18715666 DOI: 10.1016/j.jhep.2008.07.014]
29. Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-350 [PMID: 20008922 DOI: 10.3899/jrheum.090436]
30. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3-8 [PMID: 16103976 DOI: 10.1055/s-2005-915644]
31. Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 2009; 49: S35-S44 [PMID: 19399812 DOI: 10.1002/hep.22882]
32. Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in firsttime blood donors with antibodies to hepatitis B core antigen. Blood 2002; 100: 2637-2641 [PMID: 12239179 DOI: 10.1182/blood-2002-03-0798]
33. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP; Retrovirus Epidemiology Donor Study. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696-704 [PMID: 12757519 DOI: 10.1046/j.1537-2995.2003.00391.x]
34. Manzini P, Girotto M, Borsotti R, Giachino O, Guaschino R, Lanteri M, Testa D, Ghiazza P, Vacchini M, Danielle F, Pizzi A, Valpreda C, Castagno F, Curti F, Magistroni P, Abate ML, Smedile A, Rizzetto M. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007; 92: 1664-1670 [PMID: 18055990 DOI: 10.3324/haematol.11224]
35. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, Leiser S, Giordanella JP, Gueguen R, Desenclos JC. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010; 82: 546-555 [PMID: 20166185 DOI: 10.1002/jmv.21734]
36. Romanò L, Velati C, Cambiè G, Fomiatti L, Galli C, Zanetti AR; SIMTI study group for HBV infection among first-time blood donors. Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus 2013; 11: 281-288 [PMID: 23399361 DOI: 10.2450/2012.0160-12]
37. Seo DH, Whang DH, Song EY, Kim HS, Park Q. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion 2011; 51: 1840-1846 [PMID: 21332731 DOI: 10.1111/j.1537-2995.2010.03056.x]
38. Bottero J, Boyd A, Lemoine M, Carrat F, Gozlan J, Collignon A, Boo N, Dhotte P, Varsat B, Muller G, Cha O, Valin N, Nau J, Campa P, Silbermann B, Bary M, Girard PM, Lacombe K. Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region. PLoS One 2014; 9: e92266 [PMID: 24663387 DOI: 10.1371/journal. pone.0092266]
39. Tseliou P, Spiliotakara A, Dimitracopoulos GO, Christofidou M. Detection of hepatitis B virus DNA in blood units with anti-HBc as the only positive serological marker. Haematologia (Budap) 2000; 30: 159-165 [PMID: 11128108 DOI: 10.1163/1568559003001091 52]
40. Ting-Lu Z, Zhi-Ping X, Hong-Yu L, Chang-Hong G, Liang Y, Qiang D, Kai-Ling X, Yan-Ming M, Yue-He D, Ling-Yang Z. A community-based sero-epidemiological study of hepatitis B infection in Lianyungang, China, 2010. Western Pac Surveill Response J 2012; 3: 69-75 [PMID: 23908927 DOI: 10.5365/WPSAR.2011.2.1.008]
41. Lo YM, Lo ES, Mehal WZ, Sampietro M, Fiorelli G, Ronchi G, Tse CH, Fleming KA. Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients. J Clin Pathol 1993; 46: 304-308 [PMID: 8496385 DOI: 10.1136/jcp.46.4.304]
42. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008; 48: 743-746 [PMID: 18314221 DOI: 10.1016/j.jhep.2008.01.023]
43. Kim SM, Lee KS, Park CJ, Lee JY, Kim KH, Park JY, Lee JH, Kim HY, Yoo JY, Jang MK. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007; 54: 185-191 [PMID: 16564573 DOI: 10.1016/j.jinf.2006.02.002]
44. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, Lee NP, Hou JL, Liang R, Lau GK. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42: 813-819 [PMID: 15885351 DOI: 10.1016/j.jhep.2005.01.018]
45. Yotsuyanagi H, Yasuda K, Moriya K, Shintani Y, Fujie H, Tsutsumi T, Nojiri N, Juji T, Hoshino H, Shimoda K, Hino K, Kimura S, Iino S, Koike K. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion 2001; 41: 1093-1099 [PMID: 11552064 DOI: 10.1046/j.1537-2995 .2001.41091093.x]
46. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179 [PMID: 19941642 DOI: 10.1186/ar2868]
47. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-1355 [PMID: 20472596 DOI: 10.1136/ard.2009.127233]
48. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749-754 [PMID: 20535784 DOI: 10.1002/acr.20130]
49. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23 [PMID: 20668905 DOI: 10.1007/s10165-010-0337-z]
50. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-564 [PMID: 21246383 DOI: 10.1007/s00535-010-0367-5]
51. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological diseasemodifying antirheumatic drugs. Mod Rheumatol 2011; 21: 621-627 [PMID: 21528424 DOI: 10.1007/s10165-011-0458-z]
52. Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, Horita T, Yasuda S, Koike T. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol 2011; 38: 2209-2214 [PMID: 21844146 DOI: 10.3899/jrheum.110289]
53. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011; 70: 1719-1725 [PMID: 21719446 DOI: 10.1136/ard.2010.148783]
54. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012; 31: 1169-1175 [PMID: 22544263 DOI: 10.1007/s10067-012-1988-2]
55. Giardina AR, Ferraro D, Ciccia F, Ferrante A, Di Stefano R, Craxì A, Triolo G. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a twoyear prospective study. Clin Exp Rheumatol 2013; 31: 25-30 [PMID: 22935442]
56. Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ, Pang XF, Li ZG. Anti-TNF therapy in patients with HBV infection-analysis of 87 patients with inflammatory arthritis. Clin Rheumatol 2014; 33: 119-123 [PMID: 24077913 DOI: 10.1007/s10067-013-2385-1]
57. Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, Salemi S, D'Amelio R. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med 2014; 25: 482-484 [PMID: 24495663 DOI: 10.1016/j.ejim.2013.11.014]
58. Ballanti E, Conigliaro P, Chimenti MS, Kroegler B, Di Muzio G, Guarino MD, Triggianese P, Gigliucci G, Novelli L, Barbato C, Perricone R. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res 2014; 75 Suppl 1: S42-S45 [PMID: 25381975 DOI: 10.1002/ddr.21193]
59. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis 2014; Epub ahead of print [PMID: 24698305 DOI: 10.1111/1756-185X.12359]
60. Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, Iannone F, Avolio AW, Di Leo A, Cantarini L, Lapadula G. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 2015; 62: 40-46 [PMID: 25613809 DOI: 10.1002/hep.27716]
61. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-784 [PMID: 18512708 DOI: 10.1002/art.23721]
62. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975 [PMID: 20444750 DOI: 10.1136/ard.2009.126532]
63. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904 [PMID: 21540199 DOI: 10.1136/ard.2011.151027]
64. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12 [PMID: 21953336 DOI: 10.1136/annrheumdis-2011-200350]
65. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 1998; 95: 14447-14452 [PMID: 9826720 DOI: 10.1073/pnas.95.24.14447]
66. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97: 9203-9208 [PMID: 10922071 DOI: 10.1073/pnas.97.16.9203]
67. Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, Levy GA, Inman RD. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112: 381-382 [PMID: 2306066 DOI: 10.7326/0003-4819-11 2-5-381]
68. Narváez J, Rodriguez-Moreno J, Martinez-Aguilá MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998; 25: 2037-2038 [PMID: 9779869]
69. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, Kikuchi M, Yoshida K, Nakano M, Gejyo F. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339-342 [PMID: 11229464]
70. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004; 22: 375-376 [PMID: 15144137]
71. Nakanishi K, Ishikawa M, Nakauchi M, Sakurai A, Doi K, Taniguchi Y. Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A. Intern Med 1998; 37: 519-522 [PMID: 9678685 DOI: 10.2169/internalmedicine.37.519]
72. Zanati SA, Locarnini SA, Dowling JP, Angus PW, Dudley FJ, Roberts SK. Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol 2004; 31: 53-57 [PMID: 15288614 DOI: 10.1016/j.jcv.2004.02.013]
73. Yang CH, Wu TS, Chiu CT. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007; 157: 587-590 [PMID: 17596145 DOI: 10.1111/j.1365-2133.2007.08058.x]
74. Cheng J, Li JB, Sun QL, Li X. Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases. J Rheumatol 2011; 38: 181-182 [PMID: 21196589 DOI: 10.3899/jrheum.100692]
75. Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy-a report of long-term follow-up of serial cases and literature review. Clin Rheumatol 2014; 33: 577-586 [PMID: 24343455 DOI: 10.1007/s10067-013-2450-9]
76. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627-1631 [PMID: 3006059]
77. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010; 29: 1021-1029 [PMID: 20556450 DOI: 10.1007/s10067-010-1523-2]
78. Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, Ohnishi H, Seishima M, Kakumu S, Moriwaki H. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003; 77: 2469-2476 [PMID: 12551985 DOI: 10.1128/JVI.77.4.2469-2476.2003]
79. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764-3768 [PMID: 8170985 DOI: 10.1073/pnas.91.9.3764]
80. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36 [PMID: 8574849 DOI: 10.1016/S1074-7613(00)80295-2]
81. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208-217 [PMID: 18221983 DOI: 10.1016/j.semarthrit.2007.10.011]
82. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009; 76: 308-311 [PMID: 19346146 DOI: 10.1016/j.jbspin.2008.11.005]
83. Kuo SC, Lee HT, Chen WS, Chou CT, Tsai CY. Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis. BMJ Case Rep 2009; 2009: [PMID: 21686590 DOI: 10.1136/bcr.09.2008.0873]
84. Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, Park YB, Bae SC, Yoo WH, Kim SI, Lee EB, Song YW. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF? agents: a retrospective analysis of 49 cases. Clin Rheumatol 2012; 31: 931-936 [PMID: 22349880 DOI: 10.1007/s10067-012-1960-1]
85. Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-? therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 2012; 39: 269-273 [PMID: 22077677 DOI: 10.1111/j.1346-8138.2011.01434. x]
86. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 1624-1625 [PMID: 12858469]
87. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-687 [PMID: 12810441 DOI: 10.1136/ard.62.7.686]
88. Wendling D, Herbein G. TNFalpha antagonist therapy in patients with joint disease and chronic viral infection. Joint Bone Spine 2007; 74: 407-409 [PMID: 17644391 DOI: 10.1016/j.jbspin.2006.11.020]
89. Sakellariou GT, Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007; 26: 950-952 [PMID: 16865308 DOI: 10.1007/s10067-006-0392-1]
90. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35: 421-424 [PMID: 18203328]
91. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008; 14: 245-246 [PMID: 18766129 DOI: 10.1097/RHU.0b013e318181b89d]
92. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008; 27: 1069-1071 [PMID: 18521652 DOI: 10.1007/s10067-008-0896-y]
93. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009; 36: 2416-2420 [PMID: 19797507 DOI: 10.3899/jrheum.081324]
94. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B viruspositive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188-1194 [PMID: 19447932 DOI: 10.3899/jrheum.081246]
95. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol 2013; 32 Suppl 1: S47-S49 [PMID: 20379839 DOI: 10.1007/s10067-010-1438-y]
96. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010; 22: 494-499 [PMID: 20306568 DOI: 10.1097/MEG.0b013e3283329d13]
97. Mo YQ, Liang AQ, Ma JD, Chen LF, Zheng DH, Schumacher HR, Dai L. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskelet Disord 2014; 15: 449 [PMID: 25532827 DOI: 10.1186/1471-2474-15-449]
98. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-371 [PMID: 22033451 DOI: 10.1097/MD.0b013e3182380a76]
99. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-?) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol 2014; 2014: 926836 [PMID: 25114684 DOI: 10.1155/2014/926836]
100. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing antitumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013; 16: 527-531 [PMID: 24164839 DOI: 10.1111/1756-185X.12154]
101. Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ito Y, Takayanagi M, Ida N. Serum interleukin 6 levels in patients with chronic hepatitis B. Am J Gastroenterol 1991; 86: 1804-1808 [PMID: 1962626]
102. Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther 2011; 11: 533-544 [PMID: 21269234 DOI: 10.1517/14712598.2011.554810]
103. Tsuboi H, Tsujii A, Nampei A, Yoshihara H, Kawano K, Takeuchi E, Shi K. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximabreactivated hepatitis B. Mod Rheumatol 2011; 21: 701-705 [PMID: 21626075 DOI: 10.1007/s10165-011-0470-3]
104. Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Takasugi K. Successful tocilizumab treatment in a patient with adult-onset Still' s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011; 21: 215-218 [PMID: 20931272 DOI: 10.1007/s10165-010-0365-8]
105. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 2008; 47: 1838-1840 [PMID: 18854348 DOI: 10.1093/rheumatology/ken384]
106. Sharpe AH, Abbas AK. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006; 355: 973-975 [PMID: 16908487 DOI: 10.1056/NEJMp068087]
107. Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 2012; 64: 1265-1268 [PMID: 22392695 DOI: 10.1002/acr.21654]
108. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010; 149: 3-13 [PMID: 20151975 DOI: 10.1111/j.1365-2141.2010.08076.x]
109. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608 [PMID: 15934864 DOI: 10.1517/14740338.4.3.599]
110. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011; 31: 403-404 [PMID: 19830433 DOI: 10.1007/s00296-009-1202-2]
111. Andres M, Courtney P. No hepatitis B reactivation in a patient with refractory antisynthetase syndrome successfully treated with rituximab. Joint Bone Spine 2011; 78: 653-654 [PMID: 21807545 DOI: 10.1016/j.jbspin.2011.05.017]
112. Rodríguez-Escalera C, Fernández-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008; 47: 1732-1733 [PMID: 18786966 DOI: 10.1093/rheumatology/ken362]
113. Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285-289 [PMID: 21880218]
114. Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, Ballanti E, Migliore A. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol 2013; 2013: 410521 [PMID: 23606869 DOI: 10.1155/2013/410521]
115. Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2013; 72: 308-310 [PMID: 22930597 DOI: 10.1136/annrheumdis-2012-202088]
116. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31: 118-121 [PMID: 23111095]
117. Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigennegative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007; 25: 888-889 [PMID: 18173926]
118. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-720 [PMID: 18433400 DOI: 10.1111/j.1478-3231.2007.01665.x]
119. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 2010; 30: 1241-1242 [PMID: 20345703 DOI: 10.1111/j.1478-3231.2010.02238.x]
120. Germanidis G, Hytiroglou P, Zakalka M, Settas L. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 2012; 56: 1420-1421 [PMID: 22127282 DOI: 10.1016/j.jhep.2011.10.011]
121. Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 2012; 22: 470-473 [PMID: 21901356 DOI: 10.1007/s10165-011-0521-9]
122. Ghrénassia E, Mékinian A, Rouaghe S, Ganne N, Fain O. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 2012; 79: 100-101 [PMID: 21944979 DOI: 10.1016/j.jbspin.2011.07.003]
123. Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, Dalekos GN. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. World J Hepatol 2013; 5: 387-392 [PMID: 23898372 DOI: 10.4254/wjh.v5.i7.387]
124. Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia 2013; 17: 91-93 [PMID: 23935355]
125. Fanouriakis A, Vassilopoulos D, Repa A, Boumpas DT, Sidiropoulos P. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology (Oxford) 2014; 53: 195-196 [PMID: 23771951 DOI: 10.1093/rheumatology/ket221]
126. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res 2014; 44 Suppl S1: 1-58 [PMID: 24397839 DOI: 10.1111/hepr.12269]
127. Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med 2011; 22: 572-575 [PMID: 22075282 DOI: 10.1016/j.ejim.2011.09.001]
128. Huang LM, Lu CY, Chen DS. Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr Opin Immunol 2011; 23: 237-243 [PMID: 21257300 DOI: 10.1016/j.coi.2010.12.013]
129. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008; 180: 688-692 [PMID: 18178805 DOI: 10.4049/jimmunol.180.2.688]
130. Mori S. Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases? J Rheumatol 2012; 39: 1292-1293; author reply 1293 [PMID: 22661417 DOI: 10.3899/jrheum.120052]
131. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841]
132. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430 [PMID: 20049753 DOI: 10.1002/hep.23327]
133. Harigai M, Mochida S, Mimura T, Koike T, Miyasaka N. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol 2014; 24: 1-7 [PMID: 24261752 DOI: 10.3109/14 397595.2013.852834]
134. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37: 705-712 [PMID: 17894766 DOI: 10.1111/j.1445-5994.2007.01479.x]
135. Rahier JF. Prevention and management of infectious complications in IBD. Dig Dis 2012; 30: 408-414 [PMID: 22796807 DOI: 10.1159/000338143]